RSR Interviews an Antibodies CEO
And Regularly Updates this Survey of the Field (below)
The mainstream media should be running weekly headlines
updating the public on the latest progress with targeted antibody treatment.
For some reason though, for now, if you want to keep up with the latest astounding
cancer treatment developments, you'll have to keep tuning in to BEL and Real Science Radio!
* June 2018 Update: Florida woman cured of advanced breast cancer. See the BBC's report on the U.S. National Cancer Institute's amazing success with Judy Perkins, given three months to live and now recovered!
* Targeted Antibodies Cancer Treatment Revolution: Among the stunning results for targeted antibodies cancer treatment, CBS News reported on 35 terminally-ill advanced-stage leukemia sufferers. The disease went into remission in 94%, or 33 of 35 patients. Dr. Michael Grossbard, New York University's Perlmutter Cancer Center leukemia specialist told CBS News, "Oncologists are reluctant to use the word extraordinary. But these [results] are extraordinary. These are really remarkable findings..."
* FDA Approval: The FDA has approved Novartis' Kymriah to treat children with acute leukemia. Because various methods of cancer immunotherapy exist, the media and even the FDA itself will claim one or another of these early immunotherapy drugs (see below for those already approved in the U.S.) as a "first". Methods include checkpoint inhibitors and the actual modification of antibodies. See below for more. But first, there's this, right up the street from RSR's studio...
* ArcherDX in Boulder, Colorado: ArcherDX spearheaded the effort to extend the life of 12-year old Zaida. Real Science Radio host Bob Enyart interviews Archer's CEO Jason Myers to discuss Zaida's case and to get a better understanding both of this revolution in cancer treatment and of how targeted immunotherapy works. Studies in the U.S. and the U.K. are seeing hundreds of patients with many types of cancer virtually "cured", as some oncologists are now putting it. Not every patient though responds well, and some few have even died from the treatment. Update: Sadly, Zaida herself passed away on March 10, 2017 and while RSR would like to learn the specific cause, of course the family's privacy desires comes first. Overall though, the widespread success is stunning. ArcherDX provides the technology so that a patient's doctor can find out quickly what specific mutations may be causing the cancer. Now, a growing number of oncologists will be offering their patients the greatest of hope through individualized treatment that, like an archer aiming at a target, just might hit the bullseye. Online at ArcherDX.com, this next-generation sequencing (NGS) firm develops what is called target enrichment chemistry.
* Cancers Already Being Successfully Treated: People suffer from more than 100 major types of cancer. And while antibody treatment has resulted in some relatively rare autoimmune or other negative and even lethal side effects, the much more common positive treatment experiences range in degree, from stopping further tumor growth, to actually shrinking tumors, to major remission, and even to apparent cure. The types of cancer already being successfully treated with immunotherapy, using either the inhibitor or the re-targeting approach, include:
- Lung cancer (non-small cell with 30-50% response rates as of Feb. 2017)
- Childhood leukemia / leukemia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Lymph node cancer
- Melanoma skin cancer
- Kidney (renal cell) carcinoma
- Bladder (urothelial) cancer
- Head cancers
- Neck cancers
(Please don't hesitate to email updates to this list to Bob@rsr.org.)
* Targeted Antibodies Trials, Success Stories, News, and RSR Broadcasts: The public awareness of the current revolution is cancer antibody treatment should explode from the 2015 to the end of 2017. As with all medicines, patients respond with great variability. However, the following results and ongoing trials though are greatly encouraging: